甘李藥業股票討論區

Gan & Lee Pharmaceuticals' high P/S ratio may not be justified due to its slow revenue growth and the industry's better growth forecast. Investors may be disappointed if the P/S falls in line with the growth outlook, posing a significant risk of share price decline.

Gan & Lee Pharmaceuticals' high P/S ratio is likely due to investor expectations of increased revenues. However, their less than industry average projected revenue growth and recent mediocre performance might not justify this optimism.